Photocure granted patent in Europe and Russia for Visonac in the treatment of acne

01-Dec-2009

Both the European Patent Office and the Patent Office in Russia have issued decisions to grant a patent on Photocure's patent application "PDT Acne". The granted patents will provide protection for the use of the 5-ALA-ester methyl aminolevulinate (MAL- the active ingredient in VisonacTM) and other 5-ALA-esters in the treatment of acne until November 2025.

"We are very pleased with these decisions giving a strong patent protection on Photocure's lead dermatology product", says Kjetil Hestdal, President and CEO of Photocure. "Patent protection of our products is key to succeed in the market".

VisonacTM is a photodynamic therapy that combines the VisonacTM cream with illumination by a red light source to treat acne. Visonac(TM) cream contains MAL. The cream is applied to the acne area to be treated and after a short incubation time, the skin is illuminated with red light. The PDT procedure kills bacteria and appears to have a beneficial effect on sebaceous glands and inflammatory cells.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances